GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Shiller PE Ratio

AEterna Zentaris (AEterna Zentaris) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AEterna Zentaris Shiller PE Ratio Historical Data

The historical data trend for AEterna Zentaris's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Shiller PE Ratio Chart

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AEterna Zentaris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AEterna Zentaris's Shiller PE Ratio

For the Biotechnology subindustry, AEterna Zentaris's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEterna Zentaris's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Shiller PE Ratio falls into.



AEterna Zentaris Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

AEterna Zentaris's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, AEterna Zentaris's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.16/125.4675*125.4675
=-1.160

Current CPI (Dec. 2023) = 125.4675.

AEterna Zentaris Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -200.000 98.604 -254.487
201406 -225.000 99.473 -283.797
201409 -500.000 99.394 -631.160
201412 198.500 98.367 253.187
201503 -339.750 99.789 -427.176
201506 -341.250 100.500 -426.026
201509 -166.500 100.421 -208.027
201512 -25.225 99.947 -31.666
201603 -9.250 101.054 -11.485
201606 -17.750 102.002 -21.833
201609 -15.250 101.765 -18.802
201612 -18.250 101.449 -22.571
201703 -7.750 102.634 -9.474
201706 -4.500 103.029 -5.480
201709 -15.250 103.345 -18.515
201712 0.250 103.345 0.304
201803 21.750 105.004 25.989
201806 -4.000 105.557 -4.754
201809 -3.750 105.636 -4.454
201812 -8.000 105.399 -9.523
201903 -7.500 106.979 -8.796
201906 0.250 107.690 0.291
201909 -0.500 107.611 -0.583
201912 -1.000 107.769 -1.164
202003 1.000 107.927 1.163
202006 -3.750 108.401 -4.340
202009 -0.500 108.164 -0.580
202012 -0.523 108.559 -0.604
202103 -0.500 110.298 -0.569
202106 -0.430 111.720 -0.483
202109 -0.400 112.905 -0.445
202112 -0.630 113.774 -0.695
202203 -0.540 117.646 -0.576
202206 -0.870 120.806 -0.904
202209 -0.700 120.648 -0.728
202212 -2.560 120.964 -2.655
202303 -0.880 122.702 -0.900
202306 -0.520 124.203 -0.525
202309 -0.850 125.230 -0.852
202312 -1.160 125.468 -1.160

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AEterna Zentaris  (NAS:AEZS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


AEterna Zentaris Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (AEterna Zentaris) Business Description

Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.